

AD_____

Award Number: W81XWH-14-2-0193

TITLE: Prevention of Bone Loss after Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy

PRINCIPAL INVESTIGATOR: Dr. Thomas Schnitzer

CONTRACTING ORGANIZATION: Northwestern University
Evanston, IL 60208

REPORT DATE: October 2015

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.


REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 22-10-2015 October 2015		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 29 Sep 2014-28 Sep 2015	
Prevention of Bone Loss after Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy				5a. CONTRACT NUMBER W81XWH-14-2-0193	
				5b. GRANT NUMBER n/a	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Thomas J. Schnitzer, MD, PhD email: tjs@northwestern.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Northwestern University, 633 Clark St., Evanston, IL 60208-0001				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) US Army Medical Research and Materiel Command Fort Detrick, MD 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Rapid bone loss is a universal accompaniment of acute spinal cord injury (SCI) and leads to severe loss of bone mass and bone strength with a marked increased risk of fracture. This 24 month double-blind, randomized, placebo-controlled study evaluates in 60 participants the efficacy (bone mass and bone strength) and safety of zoledronic acid administered early after acute SCI to prevent bone loss, the duration of its effects and the value of using biomarkers to guide therapy. Data collection (bone imaging and biomarkers) occurs at baseline and after 3, 6 and 12 months during the first year; participants are re-randomized after 12 months with subsequent data collection at 18 and 24 months. Currently, all regulatory requirements for the study have been completed. Twelve (12) participants have been randomized and treated. No unexpected safety events have occurred. Data collection is on-going and additional patients are being screened for study entry.					
15. SUBJECT TERMS Spinal cord injury, bone mass, bone strength, osteoporosis, zoledronic acid					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 7	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	4
3. Overall Project Summary.....	4
4. Key Research Accomplishments.....	5
5. Conclusion.....	5
6. Publications, Abstracts, and Presentations.....	5
7. Inventions, Patents and Licenses.....	5
8. Reportable Outcomes.....	5
9. Other Achievements.....	5
10. References.....	5
11. Appendices.....	5
12. Quad chart.....	6

INTRODUCTION:

Rapid bone loss is a universal accompaniment of acute spinal cord injury (SCI) and leads to severe loss of bone mass and bone strength with a marked increased risk of fracture. The study proposed is a 2 year, randomized, double-blind placebo-controlled study of zoledronic acid to evaluate its efficacy and safety for the prevention of bone loss and maintenance of bone strength in individuals with recent onset SCI (see diagram below). At the end of the first year of the study, each treatment groups will be re-randomized to either zoledronic acid or placebo to evaluate the durability of response to zoledronic acid and the utility of serum bone markers to guide therapeutic decision making. DXA imaging, CT imaging and bone markers will be obtained at baseline, 3 months, 6 months, 12 months, 18 months and 24 months.



KEYWORDS: spinal cord injury, bone mass, bone strength, osteoporosis, zoledronic acid

OVERALL PROJECT SUMMARY:

All objectives outlined in the Statement of Work to be completed during the first year have been completed. All regulatory approvals have been obtained (Specific Aim 1, Major Task 1) and all study documents and materials prepared and deployed (Specific Aim 1, Major Task 2). Screening, enrollment and treatment of participants (Specific Aim 1, Major Task 3) has also commenced, with 12 participants currently randomized and active in the study. Data are being obtained and entered into the study database, and study materials are being collected and maintained for future assay (biomarkers; part of Specific Aim 2, Major Task 1) or for image analysis (CT bone scans; part of Specific Aim 3, Major Task 1). As the investigators remain blinded to allocation of treatment assignment, it is not possible to know efficacy results until the end of the study. No unexpected safety concerns have arisen. One participant developed a high fever, coincident with infusion and possible urinary tract infection. One data safety monitoring meeting has been held with the internal medical monitor with the conclusion being to continue the study without any changes.

Recruitment has been largely on track after a slightly delayed start due to delay from what was anticipated of regulatory approvals. There have been no impediments and treatment and data collection are proceeding without issues. No changes have been made in the statement of work and

only minor modifications of the protocol have been made to permit more efficient management of the study.

KEY RESEARCH ACCOMPLISHMENTS:

There are no outcome data available to date. As this is a blinded clinical trial, scientific data relating to study objectives will not be available until all participants have concluded the study, data cleaned and data base locked, and analyses completed.

CONCLUSION:

This project has not progressed to the point of being able to provide any conclusions in regard to the effect of these specific interventions on bone mass or bone quality in people after spinal cord injury. If benefit is shown, this intervention has the potential to reduce fracture incidence in people experiencing acute SCI.

PUBLICATIONS, ABSTRACTS AND PRESENTATIONS:

None.

INVENTIONS, PATENTS AND LICENSES:

None.

REPORTABLE OUTCOMES:

None.

OTHER ACHIEVEMENTS:

None.

REFERENCES:

None.

APPENDICES:

None.

Prevention of Bone Loss after Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength and Use of Biomarkers to Guide Therapy

Proposal Log Number SC130125; Award # W81XWH-14-2-0193; HRPO Log A-18350



PI: Dr. Thomas J. Schnitzer Org: Northwestern University Feinberg School of Medicine Award Amount: \$2,011,846

Study/Product Aims

- Define timing and frequency of administration of zoledronic acid that will result in optimal prevention of bone loss after acute SCI.
- Evaluate the use of serum markers of bone metabolism to guide therapeutic decisions of timing and need for retreatment with zoledronic acid after acute SCI.
- Evaluate effects of zoledronic acid in mitigating loss of bone strength that occurs after acute SCI.

Approach

This is a 2 year, randomized, double-blind placebo-controlled study. Subjects will be randomized at baseline and again at 12 months to receive either zoledronic acid or placebo each time. Subject will be followed for 24 months with repeat DXA scans, CT scans, and serum bone markers.



IRB approval received at all sites. Recruitment and enrollment has begun. 12 participants have been randomized and remain active.

Goals/Milestones

- CY14 Goals** – Begin study start-up
- Obtain regulatory approval at all sites
- CY15 Goal** – Complete start-up, Begin recruitment and enrollment
- Enroll 20-25 subjects into study
- CY16 Goal** – Continue recruitment and enrollment
- Enroll 20-25 subjects into study
- CY17 Goal** – Complete subject enrollment
- CY18 Goal** – Complete data collection and data analysis
- Final study report

Comments/Challenges/Issues/Concerns

- Delayed HRPO approval led to 2 month delay from projected timelines, altered goals: CY Goals (CY15 Goal = 20-25 subjects)
- No major changes in budget.

Budget Expenditure to Date (Sep 30, 2015)

Projected Expenditure: \$539,499

Actual Expenditure: \$287,176 (subcontract invoices outstanding)

Timeline and Cost						
Activities	CY	14	15	16	17	18
Study Start-Up Activities						
Participant Enrollment						
Data Collection and Entry						
Data Analysis						
Estimated Budget (\$K)		\$138K	\$541K	\$503K	\$465K	\$365K

Updated: 22 Sep 2015